Drug Trial Radar · NCT04136366
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Nov 15, 2019
Primary completion
Jun 14, 2022
Study completion Jun 14, 2022
Sponsor
- Lead sponsor
- Aldeyra Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.
Conditions
- Proliferative Vitreoretinopathy
Interventions
ADX-2191 (intravitreal methotrexate 0.8%)Drug
ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
Standard surgical care procedureOther
Standard surgical care performed upon completion of pars plana vitrectomy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrent Retinal Detachment Compared to Historical RatesTime frame: Efficacy assessment period (Week 1 to Week 24)
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Retinal Consultants of Arizona
Phoenix, Arizona
University of California Los Angeles
Los Angeles, California
Florida Retina Institute
Orlando, Florida
Bascom Palmer Eye Institute
Palm Beach Gardens, Florida
Emory Eye Center
Atlanta, Georgia
University of Illinois at Chicago
Chicago, Illinois
Illinois Retina Associates
Joliet, Illinois
University of Iowa
Iowa City, Iowa
Tufts Medical Center
Boston, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts
Massachusetts Eye and Ear
Boston, Massachusetts
New England Retina Consultants
Springfield, Massachusetts
Kresge Eye Institute
Detroit, Michigan
Associated Retinal Consultants
Royal Oak, Michigan
Vitreo-Retinal Surgery
Minneapolis, Minnesota
Mayo Clinic Ophthalmology
Rochester, Minnesota
The Retina Institute
St Louis, Missouri
Long Island VitreoRetinal Consultants
Forest Hills, New York
Duke Health Center
Durham, North Carolina
OHSU Casey Eye Institute
Portland, Oregon
Mid Atlantic Retina
Philadelphia, Pennsylvania
Retina Consultants of Houston
Houston, Texas
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.